Skip to main content
See every side of every news story
Published • loading... • Updated

Will It Shed the ‘Failed COVID-19 Drug’ Label? Shinpoong Pharmaceutical Seeks Breakthrough in Malaria Market Backed by Germany’s Merck

Summary by 조선일보
Shinpoong Pharmaceutical, which lost market confidence following clinical trial failures after boosting its stock price by promising to develop the malaria drug 'Pyramax' as a COVID-19 treatment, is aiming for a comeback by expanding its malaria business. This move comes as the company partners with the German pharmaceutical firm Merck to develop a new combination therapy utilizing Pyramax. The strategy is to seek new growth opportunities, given…

1 Articles

Lean Right

Shinpoong Pharmaceutical, which lost market confidence following clinical trial failures after boosting its stock price by promising to develop the malaria drug 'Pyramax' as a COVID-19 treatment, is aiming for a comeback by expanding its malaria business. This move comes as the company partners with the German pharmaceutical firm Merck to develop a new combination therapy utilizing Pyramax. The strategy is to seek new growth opportunities, given…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources lean Right
100% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

조선일보 broke the news on Tuesday, November 17, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal